Cambridge, UK, 9 September 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company which identifies and develops naturally occurring therapeutic antibodies from resilient individuals, today announced initiation of a Phase 1 first-in-human study of ATLX-1282. ATLX-1282 was licensed to Eli Lilly and Company (Lilly) in May 2025 as part of an exclusive global licensing agreement, which […]
Learn more about B cell immune repertoires from Jane Osbourn, Alchemab CSO & co-founder, presenting at the Genomics England Research Summit